Hoechst 33258: Applied Bis-Benzimide DNA Stain Workflows
2026-06-08
Hoechst 33258 empowers researchers to visualize DNA in live and fixed cells with precision, especially in workflows probing tumor pH disruption and cell cycle status. Its spectral properties, cell-permeability, and compatibility with microscopy and flow cytometry make it a cornerstone for advanced oncology and metabolic studies.
3-Bromopyruvate Restores Cetuximab Sensitivity via Autophagy
2026-06-07
This study demonstrates that co-treatment with 3-bromopyruvate and cetuximab overcomes resistance in colorectal cancer cells by triggering autophagy-dependent ferroptosis and apoptosis. The findings reveal new mechanistic targets for bypassing therapeutic resistance and inform protocols for autophagy and ferroptosis modulation in cancer research.
RIPA Lysis Buffer (Strong, without inhibitors): Technical Us
2026-06-06
RIPA Lysis Buffer (Strong, without inhibitors) delivers strong detergent-based lysis of animal cells and tissues, enabling efficient protein extraction for immunological and biochemical assays. It is ideal for workflows requiring customizable inhibitor addition and rapid sample processing. This buffer is not recommended when immediate protease or phosphatase inhibition is essential or where delays in sample handling are expected.
CD44-Driven Metabolic Rewiring in IDH1-Mutant Leukemia
2026-06-05
The reference study uncovers that CD44-mediated metabolic rewiring is a critical dependency in IDH-mutant acute myeloid leukemia (AML), enabling sustained NADPH production and accumulation of the oncometabolite 2-hydroxyglutarate. This discovery highlights a novel therapeutic avenue, suggesting that targeting both CD44 and mutant IDH1 could overcome resistance and improve outcomes in AML.
AG-120 (Ivosidenib): Reliable IDH1 Inhibition in AML Assays
2026-06-05
This article explores real-world laboratory challenges in AML research and demonstrates how AG-120 (Ivosidenib), mutant IDH1 inhibitor (SKU B7805), delivers robust solutions for cell viability, 2-hydroxyglutarate reduction, and myeloid differentiation workflows. Drawing on published data and validated protocols, it addresses experimental design, troubleshooting, and product reliability for scientists seeking reproducible, data-backed results.
Jasplakinolide: Precision Actin Polymerization Inducer in Re
2026-06-04
Jasplakinolide stands out as a membrane-permeable actin polymerization inducer, enabling unparalleled control over cytoskeletal dynamics in both basic and translational research. With optimized workflows, robust troubleshooting strategies, and unique assay flexibility, APExBIO’s Jasplakinolide empowers researchers to dissect actin-dependent processes with unmatched precision.
EZ Cap™ Firefly Luciferase mRNA: Optimizing mRNA Delivery As
2026-06-04
EZ Cap™ Firefly Luciferase mRNA, featuring a Cap 1 structure and optimized poly(A) tail, unlocks reliable, high-sensitivity bioluminescent assays for gene regulation and in vivo imaging. Its robust design streamlines mRNA delivery workflows, enhances translation efficiency, and enables reproducible results even in challenging experimental setups.
ML133 HCl: Precision Potassium Channel Inhibitor for Kir2.1
2026-06-03
ML133 HCl is a highly selective potassium channel inhibitor, enabling researchers to dissect Kir2.1 function in cardiovascular and pulmonary artery smooth muscle cell studies with confidence. Its robust selectivity, solubility, and protocol flexibility make it an indispensable tool for modeling disease mechanisms and validating novel therapeutic targets.
Biotin (Vitamin B7): Coenzyme Function & Research Applicatio
2026-06-03
Biotin (Vitamin B7) is an essential water-soluble B-vitamin and a crucial coenzyme for multiple carboxylases. APExBIO’s high-purity Biotin A8010 supports precise protein biotinylation and sensitive molecular detection in research workflows. This article details the molecular rationale, mechanistic action, and validated protocols for using biotin in metabolic and labeling studies.
Targeted mRNA Delivery to Islet β Cells via Lipid Nanopartic
2026-06-02
Enriquez et al. developed an eGLP-conjugated lipid nanoparticle system that enables efficient, β cell-selective mRNA delivery in mouse and human models. This platform demonstrates functional mRNA expression in islet β cells and delays autoimmune diabetes progression, offering a new avenue for mRNA-based β cell modulation.
Optimizing ARCA Capped mRNA Synthesis: Insights From HyperSc
2026-06-02
Discover how the HyperScribe All in One mRNA Synthesis Kit empowers next-generation mRNA vaccine synthesis with precise ARCA capping and polyadenylation. This in-depth guide analyzes the latest mechanistic research and offers unique protocol insights for translational and immunotherapy applications.
QPRT Drives Breast Cancer Invasiveness via Purinergic Signal
2026-06-01
This study demonstrates that quinolinate phosphoribosyltransferase (QPRT) enhances breast cancer cell invasiveness by modulating myosin light chain phosphorylation through purinergic receptor signaling. Pharmacological inhibition, including the use of a selective P2Y11 antagonist, reverses these invasive phenotypes, highlighting the pathway's potential as a therapeutic target.
Estradiol and the Estrogen Receptor–Autophagy Axis: New Hori
2026-06-01
Explore how estradiol, the potent estrogen steroid hormone, orchestrates multi-organ protection via the estrogen receptor–autophagy axis. This article delves deeply into mechanistic insights and translational implications, bringing new clarity to 17 beta-estradiol’s role in experimental and therapeutic research.
Pam3CSK4: Potent TLR1/2 Agonist for Innate Immune Activation
2026-05-31
Pam3CSK4 is a synthetic TLR1/2 agonist that reliably triggers innate immune pathways and modulates inflammatory responses in preclinical models. It activates key signaling cascades in immune cells, induces robust nitric oxide and cytokine production, and is validated in both allergic airway and neuro-immune research. Its specificity and reproducibility make it central to studies of immune cell activation.
Liproxstatin-1 in Fungal Ferroptosis: A New Frontier in Anti
2026-05-30
Explore how Liproxstatin-1, a leading ferroptosis inhibitor, is transforming antifungal research by targeting iron-dependent cell death in Candida albicans. This article uniquely bridges mammalian and fungal ferroptosis, offering deep insights for advanced assay design.
460 records 16/31 page Previous Next First page 上5页 1617181920 下5页 Last page